MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wardlaw, S. A.
Right arrow Articles by Belinsky, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wardlaw, S. A.
Right arrow Articles by Belinsky, S. A.

Vol. 62, Issue 2, 326-333, August 2002

Transcriptional Regulation of Basal Cyclooxygenase-2 Expression in Murine Lung Tumor-Derived Cell Lines by CCAAT/Enhancer-Binding Protein and Activating Transcription Factor/cAMP Response Element-Binding Protein

Sarah A. Wardlaw, Na Zhang, and Steven A. Belinsky

Department of Thoracic/Head and Neck Medical Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, Texas (S.A.W., N.Z.); and Molecular Biology and Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico (S.A.B.)

Cyclooxygenase-2 (COX-2) is frequently expressed in cancer cells, contributing to tumor development. Most studies of COX-2 expression have examined artificially induced expression in noncancer cells rather than basal expression in cancer cells. Therefore, basal COX-2 expression and its regulation were examined in cell lines derived from a murine model of lung adenocarcinoma. The presence of COX-2 protein in these cells was demonstrated by Western analysis. COX-2 promoter activity was repressed by U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene], a mitogen-activated protein kinase kinase inhibitor, as well as SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole], an inhibitor of p38 mitogen-activated protein kinase, substantiating the involvement of these signal transduction pathways in the regulation of basal COX-2 expression. Retinoic acid also repressed promoter activity, yet increased activity significantly in one cell line after 18 and 30 h of treatment. Deletions of the murine COX-2 promoter revealed that the 5' transcription factor binding sites were not required for basal expression, including the only nuclear factor-kappa B sites of the promoter. Site-directed mutagenesis of the 3' C/EBP (CCAAT/enhancer-binding protein) sites inhibited promoter activity by 20 to 55%, while mutation of the 3' ATF/CREB/AP-1 (activating transcription factor/cAMP response element-binding protein/activator protein-1) site inhibited activity by 70%. Mutation of the 3' upstream stimulatory factor site did not affect promoter activity. Electrophoretic mobility shift assays indicated that the AP-1 transcription factor does not bind to the 3' ATF/CREB/AP-1 site, leaving C/EBP and ATF/CREB as the major transcriptional regulators of basal expression of COX-2 in these lung tumor-derived cell lines and identifying new targets for the prevention/treatment of lung cancer through the modulation of COX-2 expression.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
H. Sun, W.-C. Chung, S.-H. Ryu, Z. Ju, H. T. Tran, E. Kim, J. M. Kurie, and J. S. Koo
Cyclic AMP-Responsive Element Binding Protein- and Nuclear Factor-{kappa}B-Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis
Cancer Prevention Research, October 1, 2008; 1(5): 316 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z. P. Lin, Y.-L. Zhu, D. R. Johnson, K. P. Rice, T. Nottoli, B. C. Hains, J. McGrath, S. G. Waxman, and A. C. Sartorelli
Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response
Mol. Pharmacol., January 1, 2008; 73(1): 243 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. R. Edwards, J. Haas, R. A. Panettieri Jr., M. Johnson, and S. L. Johnston
Corticosteroids and beta2 Agonists Differentially Regulate Rhinovirus-induced Interleukin-6 via Distinct Cis-acting Elements
J. Biol. Chem., May 25, 2007; 282(21): 15366 - 15375.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. Fang, D. Chen, and C. S. Yang
Dietary Polyphenols May Affect DNA Methylation
J. Nutr., January 1, 2007; 137(1): 223S - 228S.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. L. Eisinger, L. D. Nadauld, D. N. Shelton, P. W. Peterson, R. A. Phelps, S. Chidester, D. M. Stafforini, S. M. Prescott, and D. A. Jones
The Adenomatous Polyposis Coli Tumor Suppressor Gene Regulates Expression of Cyclooxygenase-2 by a Mechanism That Involves Retinoic Acid
J. Biol. Chem., July 21, 2006; 281(29): 20474 - 20482.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-J. Yeo, D. Gravis, J.-G. Yoon, and A.-K. Yi
Myeloid Differentiation Factor 88-dependent Transcriptional Regulation of Cyclooxygenase-2 Expression by CpG DNA: ROLE OF NF-{kappa}B AND p38
J. Biol. Chem., June 13, 2003; 278(25): 22563 - 22573.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Heuze-Vourc'h, L. Zhu, K. Krysan, R. K. Batra, S. Sharma, and S. M. Dubinett
Abnormal Interleukin 10R{alpha} Expression Contributes to the Maintenance of Elevated Cyclooxygenase-2 in Non-Small Cell Lung Cancer Cells
Cancer Res., February 15, 2003; 63(4): 766 - 770.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics